One Dose of Psilocybin Offers Long-Lasting Relief from Depression, Study Reveals

One Dose of Psilocybin Offers Long-Lasting Relief from Depression, Study Reveals

Psilocybin, the active compound found in magic mushrooms, has been linked to significant reductions in depression symptoms, providing relief for up to five years following a single treatment, as per findings from a recent study.

The groundbreaking research was presented on June 18 at the Psychedelic Science 2025 conference in Denver. It focused on individuals diagnosed with major depressive disorder (MDD) who participated in a previous psilocybin trial in 2020.

Study co-author Alan Davis, who leads the Center for Psychedelic Drug Research and Education at The Ohio State University, noted that most trial participants reported lasting improvements in their depressive symptoms, which persisted for as long as five years after their treatment.

Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, expressed optimism about psilocybin’s potential as a treatment for MDD and other mental health disorders. He indicated that these results underscore the exciting possibilities offered by psychedelic therapies.

Earlier studies had hinted at psilocybin’s antidepressant properties, prompting researchers to conduct this pioneering randomized clinical trial.

Overview of the Initial Trial

The previous trial, published in JAMA Psychiatry, included 24 participants who met the criteria for major depressive disorder. It utilized a staggered approach, with half of the participants receiving psilocybin at the onset of the study, while the remaining participants received the treatment eight weeks later.

All subjects underwent extensive psychotherapy sessions totaling 11 hours.

Positive Findings Post-Treatment

One month following their treatment, 17 of the patients reported experiencing symptom relief, and 14 of those individuals achieved full remission from their depression. Researchers noted that the effectiveness of psilocybin therapy, particularly following a limited number of doses, presents a significant advantage over traditional antidepressants that necessitate daily use.

The current study aimed to reassess 21 of the original trial participants to ascertain the longer-term effects of psilocybin on their mental health.

Long-Term Efficacy of Psilocybin

Impressively, 67 percent of participants reported being in remission from depression five years post-treatment. Additionally, these individuals experienced reduced anxiety levels and found daily functioning easier.

Even among those whose depressive symptoms returned, many maintained improved attitudes and perspectives, allowing them to engage in activities that brought them meaning and satisfaction. Davis indicated that these findings, while anecdotal, are promising, although he acknowledged the need for more rigorous studies.

External Influences on Mental Health

Experts agree that various other factors, including psychotherapy and alternative medications, likely influenced the participants’ long-term mental health improvements. Davis stated that the study does not fully account for other possible changes that may have influenced participants’ mental health over the five years since the initial trial.

Psilocybin and Other Mental Health Conditions

The research surrounding psilocybin extends beyond major depressive disorder. Psilocybin’s potential role in treating postpartum depression (PPD), which affects approximately one in seven new mothers, has also garnered interest. A 2022 study explored how psychedelics could help rekindle a sense of connection in new mothers.

In February, the Cleveland Clinic announced an upcoming study focusing on the effects of single-dosing psilocybin as a potential intervention for PPD. Currently in its second phase, the trial investigates RE104, a proprietary drug similar to psilocybin.

The Importance of Safe Administration

Ryan Moss, chief science officer at Filament Health, a company specializing in natural psychedelic drug development, emphasized the necessity of administering psychedelics in controlled environments when treating mental health issues. He noted that psychedelic experiences can involve anxiety, hallucinations, and paranoia.

Moss remarked that some patients in traditional psychedelic studies have reported experiencing adverse cardiovascular events, underlining the critical need for thorough preparation and professional monitoring during these therapeutic sessions.

Expert Perspectives on Psychedelic Research

Dr. Marc Siegel, a clinical professor at NYU Langone Medical Center, previously discussed the therapeutic potential of psychedelics with leading experts in the field. Both Dr. Rachel Yehuda and Dr. Charles Marmar acknowledged the possibility of therapeutic benefits with careful management under medical supervision, cautioning against unregulated recreational use.

This sentiment emphasizes the imperative for medical oversight when utilizing psychedelics in therapeutic contexts.

As research progresses, the implications of psilocybin and its potential role in mental health treatment may reshape our understanding of effective therapeutic practices.

Reporting by Melissa Rudy and Angelica Stabile contributed to this article.